Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Restricted access

In recent years, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain have undergone substantial revisions focusing on the appropriate and safe prescription of opioid analgesics, optimization of nonopioid analgesics and adjuvant medications, and integration of nonpharmacologic methods of cancer pain management. This selection highlights some of these changes, covering topics on management of adult cancer pain including pharmacologic interventions, nonpharmacologic interventions, and treatment of specific cancer pain syndromes. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional aspects of this topic, including pathophysiologic classification of cancer pain syndromes, comprehensive pain assessment, management of pain crisis, ongoing care for cancer pain, pain in cancer survivors, and specialty consultations.

Individual Disclosures for the NCCN Adult Cancer Pain Panel

TU1
  • 1.

    Merskey H, Bugduk N. Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd Ed. IASP Press, Seattle, WA. 1994.

    • Export Citation
  • 2.

    van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437–1449.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Te Boveldt N, Vernooij-Dassen M, Burger N, . Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 2013;16:379–389.

    • Search Google Scholar
    • Export Citation
  • 4.

    Temel JS, Greer JA, Muzikansky A, . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–742.

  • 5.

    Zimmermann C, Swami N, Krzyzanowska M, . Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014;383:1721–1730.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Grudzen CR, Richardson LD, Johnson PN, . Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial. JAMA Oncol 2016;2:591–598.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Ferrell B, Sun V, Hurria A, . Interdisciplinary palliative care for patients with lung cancer. J Pain Symptom Manage 2015;50:758–767.

  • 8.

    Bakitas MA, Tosteson TD, Li Z, . Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 2015;33:1438–1445.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Bakitas M, Lyons KD, Hegel MT, . Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741–749.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Greco MT, Roberto A, Corli O, . Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 2014;32:4149–4154.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Fairchild A. Under-treatment of cancer pain. Curr Opin Support Palliat Care 2010;4:11–15.

  • 12.

    Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000;17:70–83.

  • 13.

    Cleeland CS, Gonin R, Hatfield AK, . Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592–596.

  • 14.

    Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage 1997;14:99–117.

  • 15.

    Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1–18.

  • 16.

    Stjernswärd J. WHO cancer pain relief programme. Cancer Surv 1988;7:195–208.

  • 17.

    Stjernswärd J, Colleau SM, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage 1996;12:65–72.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    U.S. Food and Drug Administration. Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Stratgey (REMS). Silver Spring, MD: 2014. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM289730.pdf. Accessed March 7, 2019.

  • 19.

    U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). Silver Spring, MD: 2015. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. Accessed March 7, 2019.

  • 20.

    Stewart M, Brown JB, Donner A, . The impact of patient-centered care on outcomes. J Fam Pract 2000;49:796–804.

  • 21.

    Syrjala KL, Abrams JR, Polissar NL, . Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain 2008;135:175–186.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Mercadante SL, Berchovich M, Casuccio A, . A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007;24:13–19.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    American Pain Society. Principles of Analgesic Use, 7th Ed. American Pain Society, Glenview, IL. 2016.

  • 24.

    Stockler M, Vardy J, Pillai A, . Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389–3394.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–1346.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Israel FJ, Parker G, Charles M, . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010;39:548–554.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. 2011. Available at: http://www.fda.gov/drugs/drugsafety/ucm239821.htm. Accessed March 7, 2019.

  • 28.

    U.S. Food and Drug Administration. Information for Healthcare Professionals: concomitant use of ibuprofen and aspirin. 2006. Available at: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm161282.pdf. Accessed March 7, 2019.

  • 29.

    Tielemans MM, Eikendal T, Jansen JB, . Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010;33:443–453.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Laine L, Curtis SP, Cryer B, . Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010;32:1240–1248.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: https://www.fda.gov/drugs/drugsafety/ucm451800. Accessed April 12, 2019.

  • 32.

    Bally M, Dendukuri N, Rich B, . Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9:571–591.

  • 34.

    Manfredi PL, Gonzales GR, Sady R, . Neuropathic pain in patients with cancer. J Palliat Care 2003;19:115–118.

  • 35.

    Jongen JL, Huijsman ML, Jessurun J, . The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage 2013;46:581–590 e581.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Jin Y, Desta Z, Stearns V, . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Haque R, Shi J, Schottinger JE, . Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108:(3)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Azoulay L, Dell’Aniello S, Huiart L, . Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 2011;126:695–703.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27–47.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Baron R, Brunnmüller U, Brasser M, . Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. Eur J Pain 2008;12:850–858.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Chen DL, Li YH, Wang ZJ, . The research on long-term clinical effects and patients’ satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Medicine (Baltimore) 2016;95:e5144.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Dou Z, Jiang Z, Zhong J. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol 2017;13:e57–e64.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Bar Ad V, Weinstein G, Dutta PR, . Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 2010;116:4206–4213.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Raptis E, Vadalouca A, Stavropoulou E, . Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract 2014;14:32–42.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology (Williston Park) 2001;15:225–234., discussion 234–236.

  • 46.

    Haywood A, Good P, Khan S, . Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev 2015;4:CD010756.

    • Search Google Scholar
    • Export Citation
  • 47.

    Donovan KA, Chang YD, Oberoi-Jassal R, . Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care [published online February 22, 2019]. J Palliat Med. doi: 10.1089/jpm.2018.0533

    • Search Google Scholar
    • Export Citation
  • 48.

    Steele G, Arneson T, Zylla D. A comprehensive review of cannabis in patients with cancer: availability in the USA, general efficacy, and safety. Curr Oncol Rep 2019;21:10.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    National Center for Complementary and Integrative Health. Marijuana and Cannabinoids. 2019. Available at: https://nccih.nih.gov/health/marijuana. Accessed April 25, 2019.

  • 50.

    Drugs of Abuse: a DEA Resource Guide; 2017. Available at: https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf.

  • 51.

    Pergam SA, Woodfield MC, Lee CM, . Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 2017;123:4488–4497.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Tringale KR, Huynh-Le MP, Salans M, . The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014. Cancer 2019;125:2242–2251.

    • Search Google Scholar
    • Export Citation
  • 53.

    Johnson JR, Burnell-Nugent M, Lossignol D, . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39:167–179.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Portenoy RK, Ganae-Motan ED, Allende S, . Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012;13:438–449.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014;47:166–173.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Monte AA, Shelton SK, Mills E, . Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019;170:531–537.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57.

    Cherny NI. The pharmacologic management of cancer pain. Oncology (Williston Park) 2004;18:1499–1515., discussion 1516, 1520–1521., 1522, 1524.

  • 58.

    Bandieri E, Romero M, Ripamonti CI, .Early Strong Opioid Treatment Study (ESOT) Investigators. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016;34:436–442.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Andersen G, Jensen NH, Christrup L, . Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliat Med 2002;16:107–114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524–528.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 2017;25:661–675.

  • 62.

    Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol 2010;11:484–489.

  • 63.

    Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000;55:713–719.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Klepstad P, Kaasa S, Skauge M, . Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000;44:656–664.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Foley KM. The treatment of pain in the patient with cancer. CA Cancer J Clin 1986;36:194–215.

  • 66.

    Tiseo PJ, Thaler HT, Lapin J, . Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995;61:47–54.

  • 67.

    Portenoy RK, Foley KM, Stulman J, . Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991;47:13–19.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Trescot AM, Datta S, Lee M, . Opioid pharmacology. Pain Physician 2008; 11(2, Suppl)S133–S153.

  • 69.

    Mercadante S, Vellucci R, Cuomo A, . Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer 2015;23:1349–1354.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Caraceni A, Hanks G, Kaasa S, .European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58–e68.

    • Search Google Scholar
    • Export Citation
  • 71.

    Hadley G, Derry S, Moore RA, . Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013;10:CD010270.

  • 72.

    Wang DD, Ma TT, Zhu HD, . Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther 2018; 14(8, Supplement)14–21.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73.

    Kornick CA, Santiago-Palma J, Khojainova N, . A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 2001;92:3056–3061.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Portenoy RK, Taylor D, Messina J, . A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805–811.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 2009;115:2571–2579.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Kleeberg UR, Filbet M, Zeppetella G. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011;11:185–190.

  • 77.

    Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain 1997;1:185–190.

  • 78.

    Kirchheiner J, Schmidt H, Tzvetkov M, . Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257–265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29(Suppl):57–66.

  • 80.

    Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med 2004;7:545–550.

  • 81.

    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409–420.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Han HS, Lee KH, Lee KH, . A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. Support Care Cancer 2014;22:741–750.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Yu S, Shen W, Yu L, . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain 2014;15:835–844.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Inoue S, Saito Y, Tsuneto S, . A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Jpn J Clin Oncol 2018;48:542–547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Bao YJ, Hou W, Kong XY, . Hydromorphone for cancer pain. Cochrane Database Syst Rev 2016;10:CD011108.

  • 86.

    Davis MP, Varga J, Dickerson D, . Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003;11:84–92.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007;9:298–307.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88.

    Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911–918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Schmidt-Hansen M, Bennett MI, Arnold S, . Oxycodone for cancer-related pain. Cochrane Database Syst Rev 2017;8:CD003870.

  • 90.

    Schmidt-Hansen M, Bennett MI, Arnold S, . Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. BMJ Support Palliat Care 2018;8:117–128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Ahmedzai SH, Nauck F, Bar-Sela G, . A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50–60.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Ahmedzai SH, Leppert W, Janecki M, . Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer 2015;23:823–830.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442–451.

  • 94.

    McPherson ML, Walker KA, Davis MP, . Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. J Pain Symptom Manage 2019;57:635–645.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Nicholson AB, Watson GR, Derry S, . Methadone for cancer pain. Cochrane Database Syst Rev 2017;2:CD003971.

  • 96.

    Parsons HA, de la Cruz M, El Osta B, . Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520–528.

  • 97.

    Courtemanche F, Dao D, Gagné F, . Methadone as a coanalgesic for palliative care cancer patients. J Palliat Med 2016;19:972–978.

  • 98.

    Fürst P, Lundström S, Klepstad P, . Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med 2018;21:177–181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Krantz MJ, Lewkowiez L, Hays H, . Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501–504.

  • 100.

    Krantz MJ, Kutinsky IB, Robertson AD, . Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802–805.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 101.

    Kornick CA, Kilborn MJ, Santiago-Palma J, . QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499–506.

  • 102.

    Reddy S, Hui D, El Osta B, . The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010;13:33–38.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Chou R, Cruciani RA, Fiellin DA, .Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014;15:321–337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    McNulty JP. Can levorphanol be used like methadone for intractable refractory pain? J Palliat Med 2007;10:293–296.

  • 105.

    Atkinson TJ, Fudin J, Pandula A, . Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther 2013;35:1669–1689.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Rowbotham MC, Twilling L, Davies PS, . Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223–1232.

  • 107.

    Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician 2015;18:395–400.

  • 108.

    Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879–923.

  • 109.

    Grond S, Radbruch L, Meuser T, . High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999;18:174–179.

  • 110.

    Rodriguez RF, Bravo LE, Castro F, . Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007;10:56–60.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017;5:CD012508.

  • 112.

    Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804–2818.

  • 113.

    Hartrick CT, Rodríguez Hernandez JR. Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother 2012;13:283–286.

  • 114.

    Afilalo M, Etropolski MS, Kuperwasser B, . Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489–505.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Buynak R, Shapiro DY, Okamoto A, . Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787–1804.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Schwartz S, Etropolski M, Shapiro DY, . Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27:151–162.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Mercadante S, Porzio G, Ferrera P, . Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012;28:1775–1779.

  • 118.

    Mercadante S, Porzio G, Adile C, . Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin 2014;30:2063–2068.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Naing C, Aung K, Racloz V, . Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol 2013;139:1963–1970.

  • 120.

    Pergolizzi JV, Jr., Mercadante S, Echaburu AV, .Euromed Communications meeting. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009;25:1517–1528.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 121.

    Deandrea S, Corli O, Moschetti I, . Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag 2009;5:707–718.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Melilli G, Samolsky Dekel BG, Frenquelli C, . Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10:85–93.

  • 123.

    Lundorff L, Sjøgren P, Hansen OB, . Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag 2013;9:255–262.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 124.

    Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297–326.

  • 125.

    Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2017;6:CD003351.

  • 126.

    Hardy J, Quinn S, Fazekas B, . Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611–3617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Bredlau AL, Thakur R, Korones DN, . Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 2013;14:1505–1517.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 128.

    DeWilde KE, Levitch CF, Murrough JW, . The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci 2015;1345:47–58.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Fond G, Loundou A, Rabu C, . Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014;231:3663–3676.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Lee EE, Della Selva MP, Liu A, . Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015;37:178–184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Sharma S, Rajagopal MR, Palat G, . A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009;37:85–93.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Jendoubi A, Naceur IB, Bouzouita A, . A comparison between intravenous lidocaine and ketamine on acute and chronic pain after open nephrectomy: A prospective, double-blind, randomized, placebo-controlled study. Saudi J Anaesth 2017;11:177–184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2004;2:90–94.

  • 134.

    Carroll I. Intravenous lidocaine for neuropathic pain: diagnostic utility and therapeutic efficacy. Curr Pain Headache Rep 2007;11:20–24.

  • 135.

    Bruera E, Kim HN. Cancer pain. JAMA 2003;290:2476–2479.

  • 136.

    Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695–1700.

  • 137.

    Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the management of cancer pain. Cancer Contr 2000;7:132–141.

  • 138.

    Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003;17:248–256.

  • 139.

    Nijland L, Schmidt P, Frosch M, . Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer 2019;27:33–42.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Davies A, Buchanan A, Zeppetella G, . Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619–628.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013;10:CD004311.

    • Search Google Scholar
    • Export Citation
  • 142.

    Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72:181–190.

  • 143.

    Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46:573–580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage 2014;47:772–785.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    VA/DoD clinical practice guideline for opioid therapy for chronic pain. Version 3.0. 2017. Available at: https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf. Accessed March 7, 2019.

  • 146.

    Butler SF, Budman SH, Fernandez KC, . Development and validation of the Current Opioid Misuse Measure. Pain 2007;130:144–156.

  • 147.

    Meltzer EC, Rybin D, Saitz R, . Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain 2011;152:397–402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Anghelescu DL, Ehrentraut JH, Faughnan LG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw 2013;11:1023–1031.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    McNicol E, Horowicz-Mehler N, Fisk RA, .Americal Pain Society. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231–256.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 150.

    Mercadante S. Comments on Wang et al., PAIN, 67 (1996) 407-416. Pain 1998;74:106–107.

  • 151.

    Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998;74:5–9.

  • 152.

    Wilson RK, Weissman DE. Neuroexcitatory effects of opioids: patient assessment #57. J Palliat Med 2004;7:579–581.

  • 153.

    Moryl N, Carver A, Foley KM. Pain and palliation. In: Holland JF, Frei E, eds. Cancer Medicine. Vol. I7th ed. Hamilton, ON: BC Decker Inc; 2006:1113-1124.

  • 154.

    Moryl N, Obbens EA, Ozigbo OH, . Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol 2006;4:111.

  • 155.

    Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, . Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851–858.

  • 156.

    Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care 2005;3:227–237.

  • 157.

    Breitbart W, Marotta R, Platt MM, . A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231–237.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Bruera E, Belzile M, Neumann C, . A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000;19:427–435.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Challoner KR, McCarron MM, Newton EJ. Pentazocine (Talwin) intoxication: report of 57 cases. J Emerg Med 1990;8:67–74.

  • 160.

    Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage 1999;17:70–72.

  • 161.

    Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson’s disease. South Med J 1997;90:1023–1026.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 162.

    Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother 2005;39:727–731.

  • 163.

    Tarcatu D, Tamasdan C, Moryl N, . Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag 2007;3:167–170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2:130–136.

  • 165.

    Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008;11:575–581.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Tarumi Y, Wilson MP, Szafran O, . Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013;45:2–13.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    Rauck R, Slatkin NE, Stambler N, . Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract 2017;17:820–828.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Michna E, Blonsky ER, Schulman S, . Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12:554–562.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 169.

    Portenoy RK, Thomas J, Moehl Boatwright ML, . Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35:458–468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Chappell D, Rehm M, Conzen P. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1071.

  • 171.

    Sanz Rubiales A, del Valle Rivero ML. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;359:1070–1071.

  • 172.

    Thomas J, Karver S, Cooney GA, . Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332–2343.

  • 173.

    Chey WD, Webster L, Sostek M, . Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:2387–2396.

  • 174.

    Katakami N, Harada T, Murata T, . Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 2017;35:3859–3866.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Nee J, Zakari M, Sugarman MA, . Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1569–1584.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Cryer B, Katz S, Vallejo R, . A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825–1834.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Jamal MM, Adams AB, Jansen JP, . A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015;110:725–732.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Chang L, Lembo AJ, Lavins BJ, . The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther 2014;40:1302–1312.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage 2012;44:604–607.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21:1655–1663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Bruera E, Seifert L, Watanabe S, . Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996;11:147–153.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Herman TS, Einhorn LH, Jones SE, . Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295–1297.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Steele N, Gralla RJ, Braun DW Jr, . Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219–224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Sallan SE, Cronin C, Zelen M, . Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135–138.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 185.

    Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975;293:795–797.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650–660.

  • 187.

    Gagnon P, Allard P, Mâsse B, . Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412–426.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 188.

    Agar MR, Lawlor PG, Quinn S, . Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34–42.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Hirst JM, Vaughan CL, Irwin SA. Delirium: use antipsychotics when appropriate and appropriately. J Palliat Med 2017;20:799.

  • 190.

    Hui D, Frisbee-Hume S, Wilson A, . Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA 2017;318:1047–1056.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Bruera E, Macmillan K, Hanson J, . The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13–16.

  • 192.

    U.S. Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016. Available at: https://www.fda.gov/downloads/drugs/drugsafety/ucm518672.pdf. Accessed March 7, 2019.

  • 193.

    Prescribing information. NARCAN® (naloxone hydrochloride) nasal spray. 2017. Available at: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf. Accessed March 7, 2019.

  • 194.

    Coffin PO, Behar E, Rowe C, . Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016;165:245–252.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 2009;25:2133–2150.

  • 196.

    Vissers KC, Besse K, Hans G, . Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10:85–93.

  • 197.

    Schuster M, Bayer O, Heid F, . Opioid rotation in cancer pain treatment. Dtsch Arztebl Int 2018;115:135–142.

  • 198.

    Reddy A, Yennurajalingam S, Desai H, . The opioid rotation ratio of hydrocodone to strong opioids in cancer patients. Oncologist 2014;19:1186–1193.

  • 199.

    Davis MP, McPherson ML. Tabling hydromorphone: do we have it right? J Palliat Med 2010;13:365–366.

  • 200.

    Reddy A, Tayjasanant S, Haider A, . The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients. Cancer 2016;122:149–156.

  • 201.

    Reddy A, Yennurajalingam S, Reddy S, . The opioid rotation ratio from transdermal fentanyl to “strong” opioids in patients with cancer pain. J Pain Symptom Manage 2016;51:1040–1045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manage 2015;50:248–259.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Scholl L, Seth P, Kariisa M, . Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67:1419–1427.

  • 204.

    Dart RC, Surratt HL, Cicero TJ, . Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241–248.

  • 205.

    U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics. 2017. Available at: https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed December 1, 2017.

  • 206.

    FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications; 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620935.htm.

  • 207.

    FDA Education Blueprint for health care providers involved in the treatment and monitoring of patients with pain. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/rems/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf.

  • 208.

    U.S. Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm. Accessed January 28, 2019.

  • 209.

    Barclay JS, Owens JE, Blackhall LJ. Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Support Care Cancer 2014;22:1883–1888.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111:105–111.

  • 211.

    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; (3):CD005454.

  • 212.

    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010;81:1372–1373.

  • 213.

    Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573–581.

  • 214.

    Caraceni A, Zecca E, Bonezzi C, . Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909–2917.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 215.

    Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med 2011;25:553–559.

  • 216.

    Kane CM, Mulvey MR, Wright S, . Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med 2018;32:276–286.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Fleming JA, O’Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381–388.

  • 218.

    Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111–117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 219.

    Garzón-Rodríguez C, Casals Merchan M, Calsina-Berna A, . Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer 2013;21:3153–3158.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 220.

    Liu Z, Xu Y, Liu ZL, . Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol 2017;22:980–985.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 221.

    Sima L, Fang WX, Wu XM, . Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther 2012;37:27–31.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 222.

    Chow E, Meyer RM, Ding K, . Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:1463–1472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 223.

    Body JJ, Diel IJ, Lichinitzer M, . Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133–1137.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 224.

    Body JJ, Diel IJ, Bell R, . Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306–312.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 225.

    Cleeland CS, Body JJ, Stopeck A, . Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013;119:832–838.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 226.

    Rosen LS, Gordon D, Kaminski M, . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 227.

    Wardley A, Davidson N, Barrett-Lee P, . Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869–1876.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 228.

    Vadhan-Raj S, von Moos R, Fallowfield LJ, . Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012;23:3045–3051.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 229.

    Martin M, Bell R, Bourgeois H, . Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012;18:4841–4849.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 230.

    Van Poznak C, Somerfield MR, Barlow WE, . Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. J Clin Oncol 2017;35:3978–3986.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 231.

    Malviya A, Gerrand C. Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: a review article. Palliat Med 2012;26:788–796.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 232.

    Dupuy DE, Liu D, Hartfeil D, . Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial. Cancer 2010;116:989–997.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 233.

    Lutz S, Berk L, Chang E, .American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965–976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 234.

    Goetz MP, Callstrom MR, Charboneau JW, . Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004;22:300–306.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 235.

    Kashima M, Yamakado K, Takaki H, . Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol 2010;194:536–541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 236.

    Li C, Zhang W, Fan W, . Noninvasive treatment of malignant bone tumors using high-intensity focused ultrasound. Cancer 2010;116:3934–3942.

  • 237.

    Napoli A, Anzidei M, Marincola BC, . Primary pain palliation and local tumor control in bone metastases treated with magnetic resonance-guided focused ultrasound. Invest Radiol 2013;48:351–358.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 238.

    Liberman B, Gianfelice D, Inbar Y, . Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 2009;16:140–146.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 239.

    Silver JK, Gilchrist LS. Cancer rehabilitation with a focus on evidence-based outpatient physical and occupational therapy interventions. Am J Phys Med Rehabil 2011; 90(5, Suppl 1)S5–S15.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 240.

    Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin 2013;63:295–317.

  • 241.

    Jones L, Fitzgerald G, Leurent B, . Rehabilitation in advanced, progressive, recurrent cancer: a randomized controlled trial. J Pain Symptom Manage 2013;46:315–325.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 242.

    Eilers J, Harris D, Henry K, . Evidence-based interventions for cancer treatment-related mucositis: putting evidence into practice. Clin J Oncol Nurs 2014; 18(Suppl)80–96.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 243.

    Riley P, Glenny AM, Worthington HV, . Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 2015; (12):CD011552.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 244.

    Idayu Mat Nawi R, Lei Chui P, Wan Ishak WZ, . Oral cryotherapy: prevention of oral mucositis and pain among patients with colorectal cancer undergoing chemotherapy. Clin J Oncol Nurs 2018;22:555–560.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 245.

    Kataoka T, Kiyota N, Shimada T, . Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx 2016;43:677–684.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 246.

    McGuire DB, Fulton JS, Park J, .Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21:3165–3177.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 247.

    Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches? Cancer Nurs 2004;27:183–205.

  • 248.

    Shih A, Miaskowski C, Dodd MJ, . A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 2002;29:1063–1080.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 249.

    Chitapanarux I, Tungkasamit T, Petsuksiri J, . Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. Support Care Cancer 2018;26:879–886.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 250.

    Epstein JB, Silverman S, Jr., Paggiarino DA, . Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92:875–885.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 251.

    Clark K, Lam L, Currow D. Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer 2009;17:1463–1468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 252.

    Deng GE, Rausch SM, Jones LW, . Complementary therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e420S–e436S.

    • Search Google Scholar
    • Export Citation
  • 253.

    Greenlee H, DuPont-Reyes MJ, Balneaves LG, . Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017;67:194–232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 254.

    Lyman GH, Greenlee H, Bohlke K, . Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018;36:2647–2655.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 255.

    Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. Eur J Cancer Care (Engl) 2017;26:e12457.

  • 256.

    Hershman DL, Unger JM, Greenlee H, . Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA 2018;320:167–176.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 257.

    Pfister DG, Cassileth BR, Deng GE, . Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010;28:2565–2570.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 258.

    Zick SM, Sen A, Hassett AL, . Impact of self-acupressure on co-occurring symptoms in cancer survivors. JNCI Cancer Spectr 2018;2:pky064.

  • 259.

    Raphael J, Hester J, Ahmedzai S, . Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 2010;11:872–896.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 260.

    Stoelb BL, Molton IR, Jensen MP, . The efficacy of hypnotic analgesia in adults: a review of the literature. Contemp Hypn 2009;26:24–39.

  • 261.

    Huang ST, Good M, Zauszniewski JA. The effectiveness of music in relieving pain in cancer patients: a randomized controlled trial. Int J Nurs Stud 2010;47:1354–1362.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 262.

    Kwekkeboom KL, Cherwin CH, Lee JW, . Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010;39:126–138.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 263.

    Cassileth BR, Keefe FJ. Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain. Oncologist 2010;15(Suppl 2):19–23.

  • 264.

    Montgomery GH, Weltz CR, Seltz M, . Brief presurgery hypnosis reduces distress and pain in excisional breast biopsy patients. Int J Clin Exp Hypn 2002;50:17–32.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 265.

    Bennett MI, Bagnall AM, José Closs S. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain 2009;143:192–199.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 266.

    Keefe FJ, Abernethy AP, C Campbell L. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 2005;56:601–630.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 267.

    Lovell MR, Luckett T, Boyle FM, . Patient education, coaching, and self-management for cancer pain. J Clin Oncol 2014;32:1712–1720.

  • 268.

    Sheinfeld Gorin S, Krebs P, Badr H, . Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 2012;30:539–547.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 269.

    Puchalski C, Ferrell B, Virani R, . Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. J Palliat Med 2009;12:885–904.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 270.

    Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol 2010;8:52–59.

  • 271.

    Eidelman A, White T, Swarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw 2007;5:753–760.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 272.

    Tay W, Ho KY. The role of interventional therapies in cancer pain management. Ann Acad Med Singapore 2009;38:989–997.

  • 273.

    Wong GY, Schroeder DR, Carns PE, . Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092–1099.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 274.

    Cheville AL, Basford JR. Role of rehabilitation medicine and physical agents in the treatment of cancer-associated pain. J Clin Oncol 2014;32:1691–1702.

  • 275.

    Arcidiacono PG, Calori G, Carrara S, . Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; (3):CD007519.

  • 276.

    Zhang CL, Zhang TJ, Guo YN, . Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain. Dig Dis Sci 2008;53:856–860.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 277.

    Zheng S, He L, Yang X, . Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore) 2017;96:e6354.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 278.

    Smith TJ, Staats PS, Deer T, .Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20:4040–4049.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 279.

    Deer TR, Prager J, Levy R, . Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15:436–466.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 280.

    Gulati A, Puttanniah V, Hung J, . Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient. Curr Pain Headache Rep 2014;18:391.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 281.

    Lauretti GR, Rizzo CC, Mattos AL, . Epidural methadone results in dose-dependent analgesia in cancer pain, further enhanced by epidural dexamethasone. Br J Cancer 2013;108:259–264.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 282.

    Rastogi R, Patel T, Swarm RA. Vertebral augmentation for compression fractures caused by malignant disease. J Natl Compr Canc Netw 2010;8:1095–1102.

  • 283.

    Tancioni F, Lorenzetti MA, Navarria P, . Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 2011;9:4–10.

  • 284.

    Gofeld M, Bhatia A, Burton AW. Vertebroplasty in the management of painful bony metastases. Curr Pain Headache Rep 2009;13:288–294.

  • 285.

    Berenson J, Pflugmacher R, Jarzem P, .Cancer Patient Fracture Evaluation (CAFE) Investigators. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011;12:225–235.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 286.

    Eleraky M, Papanastassiou I, Setzer M, . Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine. J Neurosurg Spine 2011;14:372–376.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 287.

    Zou J, Mei X, Gan M, . Kyphoplasty for spinal fractures from multiple myeloma. J Surg Oncol 2010;102:43–47.

  • 288.

    Flagg A II, McGreevy K, Williams K. Spinal cord stimulation in the treatment of cancer-related pain: “back to the origins”. Curr Pain Headache Rep 2012;16:343–349.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4874 4874 799
PDF Downloads 1774 1774 315
EPUB Downloads 0 0 0